{"transactions":[{"id":2305156,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":16875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019)."}],"balance_after":13125,"derivative":{"exercise_price":63.35,"expiration_date":"2029-11-18","underlying":"Common Stock","underlying_shares":16875},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305155,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":9625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020)."}],"balance_after":21175,"derivative":{"exercise_price":43.57,"expiration_date":"2030-11-20","underlying":"Common Stock","underlying_shares":9625},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305154,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":6285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":48.52,"expiration_date":"2027-11-17","underlying":"Common Stock","underlying_shares":6285},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305153,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":2895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":6285,"derivative":{"exercise_price":48.52,"expiration_date":"2027-11-17","underlying":"Common Stock","underlying_shares":2895},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305152,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":31664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":30,"expiration_date":"2026-11-18","underlying":"Common Stock","underlying_shares":31664},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305151,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":31.42,"expiration_date":"2025-11-20","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305150,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":9009,"price":73.42,"value":661440.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive."}],"balance_after":34982,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305149,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":3200,"price":72.65,"value":232480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive."}],"balance_after":43991,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305148,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":18076,"price":71.71,"value":1296229.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive."}],"balance_after":47191,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305147,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":2500,"price":70.56,"value":176400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive."}],"balance_after":65267,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305146,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":16875,"price":63.35,"value":1069031.25,"ownership":{"direct":true},"balance_after":67767,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305145,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":9625,"price":43.57,"value":419361.25,"ownership":{"direct":true},"balance_after":50892,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305144,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":6285,"price":48.52,"value":304948.2,"ownership":{"direct":true},"balance_after":41267,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305143,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":42260,"price":71.32,"value":3013983.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive."}],"balance_after":34982,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305142,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":8299,"price":70.75,"value":587154.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive."}],"balance_after":77242,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305141,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":2895,"price":48.52,"value":140465.4,"ownership":{"direct":true},"balance_after":85541,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305140,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":31664,"price":30,"value":949920.0,"ownership":{"direct":true},"balance_after":82646,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2305139,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-04-05T23:54:18.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":16000,"price":31.42,"value":502720.0,"ownership":{"direct":true},"balance_after":50982,"source":{"system":"sec-edgar","filing":"0001062993-22-009836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322009836/form4.xml","form_type":"4"}},{"id":2355498,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-02","kind":"exercise","acquired":false,"shares":12481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":12481},"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355497,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-01","kind":"exercise","acquired":false,"shares":24339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":12481,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":24339},"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355496,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-02","kind":"sale","acquired":false,"shares":12481,"price":70.07,"value":874543.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive."}],"balance_after":34982,"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355495,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-02","kind":"exercise","acquired":true,"shares":12481,"price":43.46,"value":542424.26,"ownership":{"direct":true},"balance_after":47463,"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355494,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":100,"price":71.06,"value":7106.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021."}],"balance_after":34982,"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355493,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":24239,"price":70.26,"value":1703032.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.97, inclusive."}],"balance_after":35082,"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2355492,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:02:38.000Z","date":"2022-03-01","kind":"exercise","acquired":true,"shares":24339,"price":43.46,"value":1057772.94,"ownership":{"direct":true},"balance_after":59321,"source":{"system":"sec-edgar","filing":"0001062993-22-006708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322006708/form4.xml","form_type":"4"}},{"id":2394834,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-16T02:44:00.000Z","date":"2022-02-14","kind":"tax_withholding","acquired":false,"shares":954,"price":62.49,"value":59615.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":34982,"source":{"system":"sec-edgar","filing":"0001062993-22-004516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004516/form4.xml","form_type":"4"}},{"id":2394833,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-16T02:44:00.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":2419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022."}],"balance_after":35936,"source":{"system":"sec-edgar","filing":"0001062993-22-004516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004516/form4.xml","form_type":"4"}},{"id":2394832,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-16T02:44:00.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":615,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022."}],"balance_after":33517,"source":{"system":"sec-edgar","filing":"0001062993-22-004516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004516/form4.xml","form_type":"4"}},{"id":2436097,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T00:54:53.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":3336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":31664,"derivative":{"exercise_price":30,"expiration_date":"2026-11-18","underlying":"Common Stock","underlying_shares":3336},"source":{"system":"sec-edgar","filing":"0001062993-22-001041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001041/form4.xml","form_type":"4"}},{"id":2436096,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-14T00:54:53.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":36820,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001062993-22-001041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001041/form4.xml","form_type":"4"}},{"id":2436095,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-14T00:54:53.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":12536,"price":70.13,"value":879149.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.90, inclusive."}],"balance_after":32902,"source":{"system":"sec-edgar","filing":"0001062993-22-001041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001041/form4.xml","form_type":"4"}},{"id":2436094,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-14T00:54:53.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":3336,"price":30,"value":100080.0,"ownership":{"direct":true},"balance_after":45438,"source":{"system":"sec-edgar","filing":"0001062993-22-001041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001041/form4.xml","form_type":"4"}},{"id":2436093,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-14T00:54:53.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":9200,"price":43.46,"value":399832.0,"ownership":{"direct":true},"balance_after":42102,"source":{"system":"sec-edgar","filing":"0001062993-22-001041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001041/form4.xml","form_type":"4"}},{"id":2486500,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":4773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":9180,"derivative":{"exercise_price":48.52,"expiration_date":"2027-11-17","underlying":"Common Stock","underlying_shares":4773},"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486499,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":46020,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":8750},"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486498,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":201,"price":90.17,"value":18124.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.25, inclusive."}],"balance_after":32902,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486497,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":899,"price":89.33,"value":80307.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.02 to $89.88, inclusive."}],"balance_after":33103,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486496,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":900,"price":88.31,"value":79479.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.01 to $88.90, inclusive."}],"balance_after":34002,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486495,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1500,"price":87.6,"value":131400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $87.92, inclusive."}],"balance_after":34902,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486494,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2700,"price":86.45,"value":233415.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.03 to $86.91, inclusive."}],"balance_after":36402,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486493,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":5736,"price":85.49,"value":490370.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.98, inclusive."}],"balance_after":39102,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486492,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1587,"price":84.81,"value":134593.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.43 to $84.98, inclusive."}],"balance_after":44838,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486491,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":4773,"price":48.52,"value":231585.96,"ownership":{"direct":true},"balance_after":46425,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486490,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":8750,"price":43.46,"value":380275.0,"ownership":{"direct":true},"balance_after":41652,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2486489,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-04T00:02:59.000Z","date":"2021-12-01","kind":"tax_withholding","acquired":false,"shares":842,"price":87.68,"value":73826.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020."}],"balance_after":32902,"source":{"system":"sec-edgar","filing":"0001062993-21-012213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012213/form4.xml","form_type":"4"}},{"id":2498911,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-24T00:43:43.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021)."}],"balance_after":28400,"derivative":{"exercise_price":75.33,"expiration_date":"2031-11-19","underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001062993-21-011509","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321011509/form4.xml","form_type":"4"}},{"id":2498910,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-24T00:43:43.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."}],"balance_after":33744,"source":{"system":"sec-edgar","filing":"0001062993-21-011509","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321011509/form4.xml","form_type":"4"}},{"id":2529363,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-03T00:33:39.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":9547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017)."}],"balance_after":13953,"derivative":{"exercise_price":48.52,"expiration_date":"2027-11-17","underlying":"Common Stock","underlying_shares":9547},"source":{"system":"sec-edgar","filing":"0001177648-21-000029","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000029/edgar.xml","form_type":"4"}},{"id":2529362,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-03T00:33:39.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":100,"price":86.21,"value":8621.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."}],"balance_after":26944,"source":{"system":"sec-edgar","filing":"0001177648-21-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000029/edgar.xml","form_type":"4"}},{"id":2529361,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-03T00:33:39.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":7495,"price":85.02,"value":637224.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive."}],"balance_after":27044,"source":{"system":"sec-edgar","filing":"0001177648-21-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000029/edgar.xml","form_type":"4"}},{"id":2529360,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-03T00:33:39.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":1952,"price":84.31,"value":164573.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive."}],"balance_after":34539,"source":{"system":"sec-edgar","filing":"0001177648-21-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000029/edgar.xml","form_type":"4"}},{"id":2529359,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-03T00:33:39.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":9547,"price":48.52,"value":463220.44,"ownership":{"direct":true},"balance_after":36491,"source":{"system":"sec-edgar","filing":"0001177648-21-000029","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000029/edgar.xml","form_type":"4"}},{"id":2543712,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-11","kind":"exercise","acquired":false,"shares":4047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":54770,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":4047},"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2543711,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-08","kind":"exercise","acquired":false,"shares":13453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":58817,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":13453},"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2543710,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-11","kind":"sale","acquired":false,"shares":4047,"price":70.3448,"value":284685.4056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive."}],"balance_after":26944,"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2543709,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-11","kind":"exercise","acquired":true,"shares":4047,"price":43.46,"value":175882.62,"ownership":{"direct":true},"balance_after":30991,"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2543708,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-08","kind":"sale","acquired":false,"shares":13453,"price":70.091,"value":942934.223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive."}],"balance_after":26944,"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2543707,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-13T22:39:01.000Z","date":"2021-10-08","kind":"exercise","acquired":true,"shares":13453,"price":43.46,"value":584667.38,"ownership":{"direct":true},"balance_after":40397,"source":{"system":"sec-edgar","filing":"0001177648-21-000027","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000027/edgar.xml","form_type":"4"}},{"id":2942915,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-16T23:35:10.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001177648-20-000055","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000055/edgar.xml","form_type":"4"}},{"id":2942914,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-16T23:35:10.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":1540,"price":42.52,"value":65480.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award."}],"balance_after":26944,"source":{"system":"sec-edgar","filing":"0001177648-20-000055","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000055/edgar.xml","form_type":"4"}},{"id":2942913,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-16T23:35:10.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020.  The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."}],"balance_after":28484,"source":{"system":"sec-edgar","filing":"0001177648-20-000055","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000055/edgar.xml","form_type":"4"}},{"id":2971518,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-21T01:34:08.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":30800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020)."}],"balance_after":30800,"derivative":{"exercise_price":43.57,"expiration_date":"2030-11-20","underlying":"Common Stock","underlying_shares":30800},"source":{"system":"sec-edgar","filing":"0001177648-20-000041","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000041/edgar.xml","form_type":"4"}},{"id":2971517,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-21T01:34:08.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":7600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."}],"balance_after":23234,"source":{"system":"sec-edgar","filing":"0001177648-20-000041","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000041/edgar.xml","form_type":"4"}},{"id":3267132,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-18T11:06:13.000Z","date":"2020-02-12","kind":"tax_withholding","acquired":false,"shares":1091,"price":52.76,"value":57561.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":15634,"source":{"system":"sec-edgar","filing":"0001177648-20-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/edgar.xml","form_type":"4"}},{"id":3267131,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-18T11:06:13.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":2925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on March 1, 2018 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2020."}],"balance_after":16725,"source":{"system":"sec-edgar","filing":"0001177648-20-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/edgar.xml","form_type":"4"}},{"id":3267130,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-18T11:06:13.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on March 1, 2018 that vested as a result of the achievement of a research and development milestone in calendar 2019 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2020."}],"balance_after":13800,"source":{"system":"sec-edgar","filing":"0001177648-20-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000009/edgar.xml","form_type":"4"}},{"id":3318774,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2020-01-06T23:20:39.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment."}],"balance_after":5250,"derivative":{"underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001177648-20-000004","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000004/edgar.xml","form_type":"4"}},{"id":3318773,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-01-06T23:20:39.000Z","date":"2019-12-16","kind":"tax_withholding","acquired":false,"shares":2331,"price":63.88,"value":148904.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award."}],"balance_after":13313,"source":{"system":"sec-edgar","filing":"0001177648-20-000004","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000004/edgar.xml","form_type":"4"}},{"id":3318772,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-01-06T23:20:39.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019.  The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."}],"balance_after":15644,"source":{"system":"sec-edgar","filing":"0001177648-20-000004","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000004/edgar.xml","form_type":"4"}},{"id":3368622,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-18T23:44:18.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019)."}],"balance_after":30000,"derivative":{"exercise_price":63.35,"expiration_date":"2029-11-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001177648-19-000036","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000036/edgar.xml","form_type":"4"}},{"id":3660709,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-14T02:33:30.000Z","date":"2019-02-12","kind":"tax_withholding","acquired":false,"shares":5356,"price":88.88,"value":476041.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":10394,"source":{"system":"sec-edgar","filing":"0001177648-19-000015","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/edgar.xml","form_type":"4"}},{"id":3660708,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-14T02:33:30.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001177648-19-000015","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/edgar.xml","form_type":"4"}},{"id":3660707,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-14T02:33:30.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019."}],"balance_after":4500,"source":{"system":"sec-edgar","filing":"0001177648-19-000015","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000015/edgar.xml","form_type":"4"}},{"id":3756823,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-21T01:04:39.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018)."}],"balance_after":20000,"derivative":{"exercise_price":81.2,"expiration_date":"2028-11-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001177648-18-000044","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000044/edgar.xml","form_type":"4"}},{"id":3809901,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"exercise","acquired":false,"shares":2955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the \"Anniversary Date\") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date."}],"balance_after":72270,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":2955},"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809900,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"sale","acquired":false,"shares":1371,"price":96.8942,"value":132841.9482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $96.46 to $97.29, inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809899,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"sale","acquired":false,"shares":602,"price":95.8449,"value":57698.6298,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.76 to $96.26, inclusive."}],"balance_after":1371,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809898,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"sale","acquired":false,"shares":1229,"price":94.7529,"value":116451.3141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $94.35 to $95.12, inclusive."}],"balance_after":1973,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809897,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"sale","acquired":false,"shares":453,"price":93.8965,"value":42535.1145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.11, inclusive."}],"balance_after":3202,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809896,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"sale","acquired":false,"shares":500,"price":93.0182,"value":46509.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.87 to $93.08, inclusive."}],"balance_after":3655,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809895,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:18:31.000Z","date":"2018-09-20","kind":"exercise","acquired":true,"shares":2955,"price":43.46,"value":128424.3,"ownership":{"direct":true},"balance_after":4155,"source":{"system":"sec-edgar","filing":"0001177648-18-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000035/edgar.xml","form_type":"4"}},{"id":3809905,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:15:46.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":904,"price":126.3953,"value":114261.3512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5.  The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions."}],"balance_after":2400,"source":{"system":"sec-edgar","filing":"0001177648-18-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000034/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-19"}},{"id":3809904,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:15:46.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":1621,"price":125.6029,"value":203602.3009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5.  The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions."}],"balance_after":3304,"source":{"system":"sec-edgar","filing":"0001177648-18-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000034/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-19"}},{"id":3809903,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:15:46.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":445,"price":124.2008,"value":55269.356,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5.  The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions."}],"balance_after":4925,"source":{"system":"sec-edgar","filing":"0001177648-18-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000034/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-19"}},{"id":3809902,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-09-21T20:15:46.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":1185,"price":123.7155,"value":146602.8675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"shares","element":"transactionShares","label":"F6","text":"The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5.  The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5.  The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions."}],"balance_after":5370,"source":{"system":"sec-edgar","filing":"0001177648-18-000034","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000034/edgar.xml","form_type":"4/A","original_submission_date":"2018-07-19"}},{"id":3837300,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"exercise","acquired":false,"shares":2955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the \"Anniversary Date\") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date."}],"balance_after":75225,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":2955},"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3837299,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":659,"price":93.4941,"value":61612.6119,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.07 to $94.03, inclusive."}],"balance_after":310,"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3837298,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":2224,"price":92.6843,"value":206129.8832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.95, inclusive."}],"balance_after":969,"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3837297,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":700,"price":91.4886,"value":64042.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $91.35 to $91.67, inclusive."}],"balance_after":3193,"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3837296,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":572,"price":90.5798,"value":51811.6456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.30 to $90.74, inclusive."}],"balance_after":3893,"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3837295,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-21T22:02:21.000Z","date":"2018-08-20","kind":"exercise","acquired":true,"shares":2955,"price":43.46,"value":128424.3,"ownership":{"direct":true},"balance_after":4465,"source":{"system":"sec-edgar","filing":"0001177648-18-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000033/edgar.xml","form_type":"4"}},{"id":3864615,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"exercise","acquired":false,"shares":2955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the \"Anniversary Date\") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date."}],"balance_after":78180,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":2955},"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3864614,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":904,"price":126.3953,"value":114261.3512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive."}],"balance_after":1510,"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3864613,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":1621,"price":125.6029,"value":203602.3009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive."}],"balance_after":2414,"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3864612,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":445,"price":124.2008,"value":55269.356,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive."}],"balance_after":4035,"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3864611,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"sale","acquired":false,"shares":2075,"price":123.7155,"value":256709.6625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive."}],"balance_after":4480,"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3864610,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-19T20:35:37.000Z","date":"2018-07-18","kind":"exercise","acquired":true,"shares":2955,"price":43.46,"value":128424.3,"ownership":{"direct":true},"balance_after":6555,"source":{"system":"sec-edgar","filing":"0001177648-18-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000031/edgar.xml","form_type":"4"}},{"id":3889078,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T21:13:02.000Z","date":"2018-06-18","kind":"exercise","acquired":false,"shares":2955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the \"Anniversary Date\") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date."}],"balance_after":81135,"derivative":{"exercise_price":43.46,"expiration_date":"2025-06-29","underlying":"Common Stock","underlying_shares":2955},"source":{"system":"sec-edgar","filing":"0001177648-18-000028","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/edgar.xml","form_type":"4"}},{"id":3889077,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-06-19T21:13:02.000Z","date":"2018-06-18","kind":"sale","acquired":false,"shares":658,"price":115.8874,"value":76253.9092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $115.65 to $116.08, inclusive."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0001177648-18-000028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/edgar.xml","form_type":"4"}},{"id":3889076,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":128329,"kind":"person","name":"Adda Nathalie","position":1,"cik":"0001646976","reported_name":"Adda Nathalie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-06-19T21:13:02.000Z","date":"2018-06-18","kind":"sale","acquired":false,"shares":2229,"price":115.0929,"value":256542.0741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $114.55 to $115.51, inclusive."}],"balance_after":4258,"source":{"system":"sec-edgar","filing":"0001177648-18-000028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000028/edgar.xml","form_type":"4"}}],"next_cursor":"2018-06-19T21:13:02.000000Z,3889076"}